GRAS Status Affirmed for Lipogen Phosphatidylserine
September 5, 2006
Lipogen Ltd., Israel, announced today that the FDA has no questions regarding the GRAS notification for its Lipogen PS (phosphatidylserine) patented product line.
This “green-light” from FDA is a significant move for Lipogen as it aims our non-bacterial PS ingredient into the functional food and beverages marketplace,” says David Rutenberg, CEO at Lipogen
Lipogen is marketing its PS product, in both powder and liquid versions, worldwide. It can be applied to various key-category applications, such as milk, yogurt products, breakfast cereals, biscuits, meal replacements etc.
Based on the FDA GRAS approval, Rutenberg expresses confidence the company will expand its sales within the food and beverage industry. “The efficacy of PS has been recognized by the FDA which allows Qualified Health Claims (May 13, 2003). The GRAS affirmation of Lipogen PS as a functional food ingredient will greatly contribute to the fulfillment of consumer demand for mental functional supplements. Baby boomers are seeking for natural brain solutions that will prevent cognitive dysfunction.”
Phosphatidylserine is mostly found in brain cells and is involved in numerous functions of neuronal activity. Lipogen PS has been clinically tested in a double-blind, placebo-controlled studies. The research showed significant memory and mental improvements in comparison to the placebo groups.
Lipogen, a leading PS developer since 1992, focuses on natural mental health solutions for dietary supplements or for enhancing foods and beverages. All Lipogen products are vegetarian and kosher certified.
For further information, please contact:
David Rutenberg, CEO
Tel: +972 544 522 355
Fax : +972 3 548 0149
E-mail: [email protected]
www.lipogen.co.il
You May Also Like